文献速递白血病

抑制SIRT5损害线粒体代谢并增强维奈克拉诱导的急性髓系白血病细胞清除

SIRT5 inhibition impairs mitochondrial metabolism and enhances venetoclax-induced elimination of acute myeloid leukemia cells.
PubMed 文献 · Leukemia · 2025-06-30

该研究通过琥珀酰化组学分析发现,敲低SIRT5后MOLM-13细胞中83个蛋白的121个赖氨酸残基琥珀酰化水平升高,并验证SIRT5与脂肪酸氧化关键分子HADHA相互作用。SIRT5在K644位点去琥珀酰化HADHA,抑制SIRT5或HADHA可增加维奈克拉敏感及耐药细胞系对维奈克拉的敏感性。

要点

  • 敲低SIRT5后MOLM-13细胞中83个蛋白的121个赖氨酸残基琥珀酰化增加。
  • SIRT5在K644位点去琥珀酰化HADHA,敲低SIRT5导致HADHA超琥珀酰化并降低其酶活性。
  • 抑制SIRT5或HADHA可增加维奈克拉敏感及耐药细胞系对维奈克拉的敏感性。

核心结论

  • 本研究揭示了SIRT5在急性髓系白血病代谢调控中的作用,为开发SIRT5靶向药物及与代谢抑制剂的联合治疗提供了有价值的信息。

研究设计与样本

  • 研究对MOLM-13细胞进行琥珀酰化组学分析,并开展分子互作验证、拟突变实验及细胞系与AML移植NSG小鼠实验。

主要发现

  • 敲低SIRT5后,MOLM-13细胞中83个蛋白的121个赖氨酸残基琥珀酰化水平升高。
  • SIRT5与脂肪酸氧化通路关键分子HADHA相互作用,敲低SIRT5导致HADHA超琥珀酰化并降低其酶活性。
  • 拟突变实验表明SIRT5在K644位点去琥珀酰化HADHA。
  • 抑制SIRT5或HADHA在维奈克拉敏感和维奈克拉耐药细胞系中均增加对维奈克拉的敏感性。
  • 敲低SIRT5增强维奈克拉对线粒体代谢的抑制,与维奈克拉联用时改善AML移植NSG小鼠的生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metabolic reprogramming is a key focus of targeted therapies in acute myeloid leukemia (AML). The mitochondrial sirtuin SIRT5 removes succinyl groups from specific lysines and impacts cell metabolism, but its role in AML tumorigenesis has not been extensively explored. A recent study highlighted that SIRT5 regulates AML cell activity by modulating glutamine metabolism, but its molecular targets in AML remain unclear. This study aims to identify the substrates of SIRT5 in AML. It was found that a total of 83 proteins with 121 lysine (K) residues showed increased succinylation after SIRT5 knockdown, as determined by succinylome analysis of MOLM-13 cells. SIRT5 was validated to interact with HADHA, a key molecule in the fatty acid oxidation pathway. Knockdown of SIRT5 resulted in hypersuccinylation and reduced enzymatic activity of HADHA. Mimetic mutations of lysine indicated that SIRT5 desuccinylates HADHA at K644. Inhibiting SIRT5 or HADHA increased sensitivity to venetoclax (VEN) in both VEN-sensitive and VEN-resistant cell lines. SIRT5 knockdown enhanced VEN-mediated suppression of mitochondrial metabolism and improved the survival of AML-transplanted NSG mice when combined with VEN. This study reveals the role of SIRT5 in AML metabolic regulation and provides valuable insights for developing SIRT5-targeted drugs and combination therapies with metabolic inhibitors.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Wang M, Zhu R, Small D, et al. SIRT5 inhibition impairs mitochondrial metabolism and enhances venetoclax-induced elimination of acute myeloid leukemia cells. Leukemia. 2025. PMID: 40588567. doi:10.1038/s41375-025-02673-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。